{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:45:14Z","timestamp":1790664314846,"version":"4.1.0"},"reference-count":14,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T00:00:00Z","timestamp":1625702400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Oncology Nursing"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.soncn.2021.151178","type":"journal-article","created":{"date-parts":[[2021,7,30]],"date-time":"2021-07-30T23:38:57Z","timestamp":1627688337000},"page":"151178","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Tisagenlecleucel Therapy: Nursing Considerations for the Outpatient Setting"],"prefix":"10.1016","volume":"37","author":[{"given":"Kathleen","family":"Cunningham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"DiFilippo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelli","family":"Henes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah L.","family":"Irwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Napier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"95","key":"10.1016\/j.soncn.2021.151178_bib0001","doi-asserted-by":"crossref","first-page":"95ra73","DOI":"10.1126\/scitranslmed.3002842","article-title":"T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia","volume":"3","author":"Kalos","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.soncn.2021.151178_bib0002","unstructured":"Novartis Pharmaceuticals. Kymriah\u00ae (tisagenlecleucel) [Package insert]. Available at: https:\/\/www.pharma.us.novartis.com\/sites\/www.pharma.us.novartis.com\/files\/kymriah.pdf. Accessed July 12, 2021."},{"key":"10.1016\/j.soncn.2021.151178_bib0003","unstructured":"Novartis Pharmaceuticals. Kymriah\u00ae (tisagenlecleucel) [Summary of product characteristics]. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/kymriah-epar-product-information_en.pdf. Accessed July 12, 2021."},{"issue":"1","key":"10.1016\/j.soncn.2021.151178_bib0004","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"Supplement_1","key":"10.1016\/j.soncn.2021.151178_bib0005","doi-asserted-by":"crossref","first-page":"4103","DOI":"10.1182\/blood-2019-129107","article-title":"Correlative analyses of patient and clinical characteristics associated with efficacy in tisagenlecleucel-treated relapsed\/refractory diffuse large B-cell lymphoma patients in the Juliet trial","volume":"134","author":"Westin","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.soncn.2021.151178_bib0006","unstructured":"Data on file. CCTL019G2201J Protocol v00. Novartis Pharmaceuticals Corp; February 11, 2020."},{"issue":"12","key":"10.1016\/j.soncn.2021.151178_bib0008","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1016\/j.bbmt.2019.08.015","article-title":"Use of chimeric antigen receptor T cell therapy in clinical practice for relapsed\/refractory aggressive B cell non-Hodgkin lymphoma: an expert panel opinion from the American Society for Transplantation and Cellular Therapy","volume":"25","author":"Jain","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.soncn.2021.151178_bib0009","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3324\/haematol.2019.229781","article-title":"Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)","volume":"105","author":"Yakoub-Agha","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.soncn.2021.151178_bib0010","series-title":"Apheresis Standard Operating Procedures Manual","article-title":"Electrolyte management and replacement for patients undergoing apheresis","author":"Irwin","year":"2019"},{"key":"10.1016\/j.soncn.2021.151178_bib0011","unstructured":"Genentech. Actemra\u00ae (tocilizumab) [Package insert]. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/125276s127,125472s040lbl.pdf. Accessed July 12, 2021."},{"issue":"303","key":"10.1016\/j.soncn.2021.151178_bib0012","doi-asserted-by":"crossref","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci Transl Med"},{"issue":"4","key":"10.1016\/j.soncn.2021.151178_bib0013","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.soncn.2021.151178_bib0014","doi-asserted-by":"crossref","first-page":"743","DOI":"10.3109\/14653241003709686","article-title":"Adverse events following infusion of T cells for adoptive immunotherapy: a 10-year experience","volume":"12","author":"Cruz","year":"2010","journal-title":"Cytotherapy"},{"issue":"2","key":"10.1016\/j.soncn.2021.151178_bib0015","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001511","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events","volume":"8","author":"Maus","year":"2020","journal-title":"J Immunother Cancer"}],"container-title":["Seminars in Oncology Nursing"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749208121000693?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749208121000693?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T07:36:35Z","timestamp":1760081795000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0749208121000693"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":14,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["S0749208121000693"],"URL":"https:\/\/doi.org\/10.1016\/j.soncn.2021.151178","relation":{},"ISSN":["0749-2081"],"issn-type":[{"value":"0749-2081","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tisagenlecleucel Therapy: Nursing Considerations for the Outpatient Setting","name":"articletitle","label":"Article Title"},{"value":"Seminars in Oncology Nursing","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.soncn.2021.151178","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"151178"}}